Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06590961
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-27
Brief Title:
UBX-303061 in Subjects with RelapsedRefractory B-Cell Malignancies
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase IaIb Open-label Dose-escalation and Dose-expansion Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamic of UBX-303061 in Subjects with RelapsedRefractory B-Cell Malignancies
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a first-in-human Phase 1a1b multicenter open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsedrefractory B-cell malignancies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None